Ocrevus effects on fatigue and thinking in veterans with MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at whether staying on Ocrevus (a medication for MS) helps with fatigue and thinking problems in veterans with MS. If you've been on Ocrevus for at least a year, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of multiple sclerosis (MS), either relapsing or progressive.
- You have been taking Ocrevus (ocrelizumab) continuously for at least 1 year.
- You have not had an MS relapse or needed steroids for MS in the last 30 months.
- You are not currently taking any other MS disease-modifying drugs in addition to Ocrevus.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
This trial tests a biosimilar drug that acts like Ocrevus to treat multiple sclerosis. It aims to help manage disease activity and slow progression, and may be an option if you have relapsing or progressive MS.
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.